In cities across the Western world, a quiet but powerful obsession is taking hold — one that promises to cheat time itself. But critics are now asking whether the multi-billion-pound longevity industry is simply repackaging age-old fears about growing older under the respectable veneer of cutting-edge science.
Rapid advances in biotechnology, genetic research, and cosmetic medicine have handed consumers an unprecedented arsenal of tools marketed as weapons against ageing. From senolytics and NAD+ supplements to deep-plane facelifts and AI-driven biological age tests, the message is consistent: getting older is a problem to be solved.
Andrea, who holds a doctorate in literature and works for a nonprofit organisation in the United States, says the social pressure she faces in her late forties is almost impossible to resist. ‘Everyone has had some work done if they can afford it,’ she explained. ‘I consider myself a feminist to my core, but if I had the money, I would get a deep-plane facelift without a second thought. I’m already saving up to have my neck done.’
Her candour reflects a broader cultural anxiety that experts argue is being quietly exploited by an industry now worth an estimated £500 billion globally. Rather than challenging society’s discomfort with older faces and bodies, longevity culture may in fact be reinforcing it — simply with more sophisticated and scientifically credible-sounding language.
Critics, including gerontologists and feminist scholars, warn that framing natural biological ageing as a disease or deficiency is not a neutral scientific position. It is, they argue, a deeply ideological one — and one with troubling consequences for how society values older people, particularly older women.
‘When we describe ageing as something to be defeated or reversed, we are implicitly telling people that their older selves are lesser,’ said one leading academic in ageing studies. ‘That is not progress. That is ageism with a research grant.’
Proponents of longevity science counter that extending healthy human life is among the most compassionate goals medicine can pursue, and that dismissing the field risks conflating genuine healthcare innovation with vanity. Nonetheless, the debate raises urgent questions about who benefits from these technologies, who can afford access to them, and what vision of human worth underpins their development.
As the longevity industry continues its rapid expansion into mainstream consumer culture, one question is becoming increasingly difficult to ignore: are we learning to live better — or simply becoming more afraid of living at all?
